Advertisement
BMRN vs IBO
Which Stock Would AI Choose? BioMarin Pharmaceutical (BMRN) vs. Impact BioMedical (IBO) Stock Comparison
Key Takeaways
- BioMarin Pharmaceutical (BMRN), a established biotech with $10.4 billion market cap, focuses on commercial therapies for rare diseases, contrasting IBO's early-stage discovery platform as a $70 million microcap.
- BMRN shares trade around $54 with year-to-date gains of 9%, showing stability amid recent acquisition of Amicus Therapeutics; IBO at $0.65 has surged 30% YTD but remains highly volatile.
- Recent market activity for BMRN driven by M&A (mergers and acquisitions) catalysts and upcoming earnings; IBO faces going concern warnings despite merger plans.
- Biotech sector exposure similar, but BMRN offers lower risk with positive EPS (earnings per share), while IBO reports losses and minimal revenue.
- Tickeron's AI tools highlight pattern-based trading opportunities across biotechs, aiding relative performance analysis.
Introduction
This stock comparison between BioMarin Pharmaceutical (BMRN) and Impact BioMedical (IBO) examines two biopharmaceutical players amid evolving market conditions. Investors seeking exposure to rare disease treatments and innovative platforms may find value in contrasting their profiles. Traders focused on momentum versus stability, or those evaluating biotech relative performance, will benefit from insights into recent developments, financial metrics, and market positioning. With biotech sentiment influenced by clinical catalysts and economic factors, this analysis highlights key trade-offs for informed decision-making in the current environment.
BMRN Overview and Recent Performance
BioMarin Pharmaceutical (BMRN) develops and commercializes therapies for rare genetic diseases, including VOXZOGO for achondroplasia and VIMIZIM for mucopolysaccharidosis. Trading at approximately $54 with a $10.4 billion market cap, the stock's 52-week range spans $50.76 to $66.28. In recent weeks, shares have shown resilience with year-to-date gains near 9%, influenced by the completion of its $4.8 billion acquisition of Amicus Therapeutics, adding Galafold for Fabry disease to its portfolio. A board leadership transition and upcoming Q1 earnings have supported sentiment, though prior inventory issues tempered gains. Trading multiples include a price-to-earnings (P/E) ratio of 30 and trailing EPS of $1.80 on $3.22 billion revenue, reflecting operational scale.
IBO Overview and Recent Performance
Impact BioMedical (IBO) focuses on discovering biopharmaceutical platforms like Linebacker for oncology and antivirals, alongside wellness products. As a microcap with $70 million market cap, shares hover at $0.65 within a 52-week range of $0.36 to $1.95. Recent market activity reveals volatility, with year-to-date returns around 30%, driven by merger extension plans with Dr. Ashley's Ltd. However, a going concern qualification in its latest 10-K filing has pressured sentiment, alongside minimal $32,000 trailing revenue and negative EPS of -$0.38. CFO share sales added to risk perceptions in recent weeks, underscoring the speculative nature of its early-stage positioning.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from over 350 AI trading bots that scan thousands of tickers across diverse strategies, timeframes, and market conditions. Currently featuring 25 standout bots, these include short-term scalpers on 5-minute charts and longer-horizon pattern traders up to 60 minutes. Performance highlights range from 51% to 88% win rates, annualized returns up to 164%, and profit factors exceeding 3.0 for select models like those targeting semiconductors or small caps. Each bot employs unique neural networks for entry/exit signals, risk management via take-profit/stop-loss corridors, and real-time copy trading via brokerage integration. Traders can filter by style—virtual, signal, or live agents—to match current volatility. Explore Trending AI Robots for data-driven insights tailored to stocks like BMRN and IBO.
Head-to-Head Comparison
BioMarin (BMRN) and Impact BioMedical (IBO) both operate in biopharma but diverge sharply in business models: BMRN generates substantial revenue from approved rare disease drugs, while IBO emphasizes preclinical platforms with negligible sales. Growth drivers for BMRN include pipeline expansion via recent M&A, contrasting IBO's reliance on merger execution. Recent momentum favors IBO's short-term pops but BMRN's steadier trend. Risk factors amplify for IBO with going concern status and illiquidity versus BMRN's diversified portfolio. Biotech sector headwinds like regulatory scrutiny affect both, yet BMRN enjoys stronger analyst backing and market sentiment.
Tickeron AI Verdict
Tickeron’s AI models would likely favor BioMarin Pharmaceutical (BMRN) over Impact BioMedical (IBO) in the current environment. BMRN demonstrates superior trend consistency through its scale, fresh acquisition catalysts, and pre-earnings positioning, offering probabilistic outperformance with lower volatility. While IBO shows speculative upside potential, its instability and risk flags reduce appeal for pattern-based strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and IBO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMRN’s FA Score shows that 1 FA rating(s) are green whileIBO’s FA Score has 0 green FA rating(s).
- BMRN’s FA Score: 1 green, 4 red.
- IBO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMRN’s TA Score shows that 6 TA indicator(s) are bullish while IBO’s TA Score has 5 bullish TA indicator(s).
- BMRN’s TA Score: 6 bullish, 4 bearish.
- IBO’s TA Score: 5 bullish, 3 bearish.
Price Growth
BMRN (@Biotechnology) experienced а +0.43% price change this week, while IBO (@Biotechnology) price change was -3.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.00%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was +1992.95%.
Reported Earning Dates
BMRN is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Biotechnology (+7.00% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BMRN | IBO | BMRN / IBO | |
| Capitalization | 10.8B | 57.4M | 18,815% |
| EBITDA | 482M | -13.79M | -3,496% |
| Gain YTD | -5.957 | 5.366 | -111% |
| P/E Ratio | 40.21 | 8.10 | 497% |
| Revenue | 3.24B | 39K | 8,312,821% |
| Total Cash | 2.22B | 20K | 11,110,000% |
| Total Debt | 1.44B | 22.9M | 6,288% |
BMRN | IBO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 95 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 100 | |
PRICE GROWTH RATING 1..100 | 53 | 64 | |
P/E GROWTH RATING 1..100 | 10 | 98 | |
SEASONALITY SCORE 1..100 | 50 | 30 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IBO's Valuation (75) in the null industry is in the same range as BMRN (82) in the Biotechnology industry. This means that IBO’s stock grew similarly to BMRN’s over the last 12 months.
IBO's Profit vs Risk Rating (100) in the null industry is in the same range as BMRN (100) in the Biotechnology industry. This means that IBO’s stock grew similarly to BMRN’s over the last 12 months.
BMRN's SMR Rating (87) in the Biotechnology industry is in the same range as IBO (100) in the null industry. This means that BMRN’s stock grew similarly to IBO’s over the last 12 months.
BMRN's Price Growth Rating (53) in the Biotechnology industry is in the same range as IBO (64) in the null industry. This means that BMRN’s stock grew similarly to IBO’s over the last 12 months.
BMRN's P/E Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for IBO (98) in the null industry. This means that BMRN’s stock grew significantly faster than IBO’s over the last 12 months.
| BMRN | IBO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 71% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 65% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 88% |
| Advances ODDS (%) | 19 days ago 58% | 19 days ago 79% |
| Declines ODDS (%) | 6 days ago 62% | 8 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 47% | 2 days ago 90% |
Advertisement
BMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with AXON. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To BMRN | 1D Price Change % | ||
|---|---|---|---|---|
| BMRN | 100% | +2.19% | ||
| AXON - BMRN | 42% Loosely correlated | -3.16% | ||
| IBO - BMRN | 42% Loosely correlated | +5.95% | ||
| VRDN - BMRN | 40% Loosely correlated | +6.01% | ||
| ARWR - BMRN | 39% Loosely correlated | +0.18% | ||
| PCVX - BMRN | 37% Loosely correlated | +1.30% | ||
More | ||||
IBO and
Correlation & Price change
A.I.dvisor indicates that over the last year, IBO has been loosely correlated with BMRN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if IBO jumps, then BMRN could also see price increases.
| Ticker / NAME | Correlation To IBO | 1D Price Change % | ||
|---|---|---|---|---|
| IBO | 100% | +5.95% | ||
| BMRN - IBO | 42% Loosely correlated | +2.19% | ||
| PSTV - IBO | 29% Poorly correlated | -5.83% | ||
| INDP - IBO | 27% Poorly correlated | -4.36% | ||
| LPCN - IBO | 27% Poorly correlated | -1.72% | ||
| ADAG - IBO | 23% Poorly correlated | -2.54% | ||
More | ||||